![]() AAVs usually need concentration after manufacturing in addition to buffer exchange at a high recovery. LNPs require fast buffer exchange to remove any organic phase without disrupting encapsulation efficiency or causing size change. Compared to biologics, development of delivery vectors like lipid nanoparticles (LNPs) and adeno-associated viruses (AAVs) is a newer research area with different challenges and opportunities to address. About this webinarīuffer exchange is a critical step to developing optimal vectors and payloads. ![]() Join us to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |